Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint

Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now. The company has recently revised its 2025 revenue guidance to $850-$900 million, down from the previous range of $900-$950 million. Despite the adjustment, management reiterated confidence in the company’s growth trajectory, pointing to contributions from an expanded sales force, new pharmacy partnerships, and progress in its pipeline.

CEO Joe Belinoff emphasized the potential of relacorilant, which has a December 30, 2025 PDUFA date. He projected that the drug could ultimately generate $3-$5 billion annually in hypercortisolism alone. Corcept Therapeutics Inc. (NASDAQ:CORT) has already established a dedicated oncology division to prepare for commercialization, with relacorilant plus nab-paclitaxel expected to launch quickly if approved.

Additional studies are underway in earlier cancer settings, other tumor types, and combination therapies, as well as in neurological and hepatic indications.

Operationally, pharmacy capacity limited Q2 revenue growth, but a second pharmacy is expected to come online by Q4, positioning the company for stronger momentum into 2026. A second pharmacy is being brought online, with financial impact expected in Q4, positioning the company for stronger momentum into 2026.

Corcept Therapeutics Inc.’s (NASDAQ:CORT) stock has doubled over the past year, and consensus still indicates another 100% return over the next 12 months. All analysts covering it have assigned it a Buy or equivalent rating.

Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders through modulation of hormone cortisol activity.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.